Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vinik, A. I.
Right arrow Articles by Ullal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vinik, A. I.
Right arrow Articles by Ullal, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:2067-2072, 2005
© 2005 by the American Diabetes Association, Inc.

Reviews/Commentaries/ADA Statements
Review

Antibodies to Neuronal Structures

Innocent bystanders or neurotoxins?

Aaron I. Vinik, MD, PHD1,2, Dharshan Anandacoomaraswamy, MD1 and Jagdeesh Ullal, MD, MS1

1 Department of Internal Medicine, The Strelitz Diabetes Institutes, Norfolk, Virginia
2 Department of Pathology and Neurobiology, Eastern Virginia Medical School, Norfolk, Virginia

Address correspondence and reprint requests to Aaron I. Vinik, MD, PhD, The Diabetes Institute, Eastern Virginia Medical School, 855 W. Brambleton Ave., Norfolk, VA 23510. E-mail: vinikai{at}evms.edu

Abbreviations: AchR, acetylcholine receptor


   INTRODUCTION
TOP
 INTRODUCTION
PROXIMAL NEUROPATHIES
 SOMATIC NEUROPATHIES
 AUTONOMIC NEUROPATHY
 REFERENCES
 
Diabetic neuropathies are a group of clinical syndromes that affect distinct regions of the nervous system, singly or combined, and markedly affect quality of life (1) and activities of daily living and increase morbidity and mortality (2). Therapy directed at the basic pathogenesis is sorely needed. Neurologic complications occur equally in type 1 and type 2 diabetes and additionally in various forms of acquired diabetes (3). Diabetic neuropathies may be diffuse somatic and involve proximal or distal nerves, occur as focal mononeuritides, and involve the autonomic nervous system (4,5).

The pathogenesis of diabetic neuropathies is multifactorial. Hyperglycemia causes nerve damage by inducing the activation of the polyol, protein kinase C, and hexosamine pathways and the accumulation of advanced glycation end products. Hyperglycemia also induces oxidative stress by enhancement of mitochondrial respiration, redox alteration, and uncoupling proteins, which leads to elevated superoxide anions (6,7). Oxidative stress depletes nitric oxide within the peripheral nerves and endothelium of the microvasculature by reducing endothelial nitric oxide synthase, altering nerve perfusion (8). In addition, there is deficiency of or a poor response to neurotrophic factors (9). However, there is now increasing evidence to suggest that autoimmunity has a role to play in the development and progression of diabetic neuropathies.

Fifty years ago, Waksman and Adams (10) suggested an autoimmune etiology of peripheral neuropathy when they injected rabbits with neuronal components to produce what they called "allergic neuritis. " To be able to implicate autoimmunity as a causative factor of neuropathy, there would have to be a clear association between the antibody and the disease; neuropathy would have to be induced by introduction or development of antibodies, and there would have to be reversal of the disease with removal or neutralization of the antibodies. Peripheral nerves are normally protected against the immune system by tight capillary endothelial junctions and the perineurium. Nerves are also a rich source of glycoproteins, lipopolysachharides, and other lipoproteins that can potentially form active antigenic material. In the autoimmune onslaught against nerves, there is first damage to the protective sheath and then to the inner components. These can be brought on by viral or bacterial infections (e.g., polio, leprosy, Lyme’s disease), neoplasms, or connective tissue disorders, and often there is strong genetic predisposition, such as HLA DR-3 and -4, in type 1 diabetes. Table 1 illustrates the association of different types of antibodies with various neuropathy syndromes.


View this table:
[in this window]
[in a new window]
  		Table 1—
 
Neurons and pancreatic ß-cells are neuroectodermal derivatives and therefore share common antigens, especially in the early stages of cellular evolution. Type 1 diabetes results from an autoimmune destruction of pancreatic ß-cells. There also may be a direct destruction of neurons by the same autoimmune process in diabetes. The pancreatic islets of Langerhans are surrounded by a Schwann cell sheath. These cells form a tight cellular mantle that envelops the endocrine islet tissue. Components of the peri-islet Schwann cells include GAD (11). There is an early appearance of anti-GAD65–specific T-cells in type 1 diabetes. Anti-GAD65 antibody is a strong predictive marker for the onset of type 1 diabetes (12). Presence of this antibody in patients with recent-onset type 1 diabetes is associated with worse glycemic control and worse peripheral nerve function, suggesting a common mechanism for ß-cell and neuronal damage (13). Patients with high GAD65 antibodies were shown to have positive correlation with motor nerve conduction velocities, F wave latencies, thermal threshold detection, and cardiovascular autonomic function (14). However, many studies have failed to show any significant relation of GAD antibodies to the development of neuropathy. These studies concluded that GAD antibodies had no effects on residual ß-cell function or diabetic neuropathy (15). There is also no association between GAD antibodies or even islet-associated protein 2/islet cell antibody 512 with autoimmunity to nervous tissue structures or cardiac autonomic functions (16). Serum collected from type 1 diabetic patients is toxic to neuroblastoma cells of the N1E-115 cell line (17). About two-thirds of the toxicity is due to autoimmune serum factors. One of the components of this serum that mediates immune destruction of neuroblastoma cells in cultures was found to be Fas-specific IgG antibodies. These antibodies bind to Fas-ligand on the surface of N1E-115 neuroblastoma cells and induce apoptosis. Serum from patients with diabetic neuropathy contains an activator of Fas-regulated apoptosis that may contribute to the pathogenesis of diabetic neuropathy (18). There is no doubt that a variety of antibodies are present in the sera of diabetic patients with neuropathy and that the sera exert apoptotic effects on neurons grown in culture, but the missing link is the relation with clinical neuropathy and the potential for reversibility with immune therapy.


   PROXIMAL NEUROPATHIES
TOP
 INTRODUCTION
 PROXIMAL NEUROPATHIES
SOMATIC NEUROPATHIES
 AUTONOMIC NEUROPATHY
 REFERENCES
 
Perhaps the clearest link between autoimmunity and neuropathy has been the demonstration of an 11-fold increased likelihood of chronic inflammatory demyelinating polyneuropathy, multiple motor polyneuropathy, vasculitis, and monoclonal gammopathies in diabetes (19). These are proximal neuropathies presenting with pain in the buttocks and thighs, fasciculation, and weakness with inability to rise from the sitting position or when kneeling on the floor. They may be the presenting symptom in many autoimmune vasculitides and celiac disease, a multigenetic, T-cell–mediated autoimmune disorder that results from a loss of tolerance to gluten (20). In support of an autoimmune mechanism for proximal neuropathies is the salutary response to intravenous Ig and immunotherapy (21).


   SOMATIC NEUROPATHIES
TOP
 INTRODUCTION
 PROXIMAL NEUROPATHIES
 SOMATIC NEUROPATHIES
AUTONOMIC NEUROPATHY
 REFERENCES
 
The situation with somatic neuropathies is less clear. Several different autoantibodies in human sera have been reported that can react with epitopes in neuronal cells. Prominent among them are the gangliosides, and antibodies to GD1a, GD1b, GM1, GM2, GalNAc-GD1a, etc., are not uncommon. Other antibodies include anti-sulfatide, anti–myelin-associated glycoprotein, anti-Hu (associated with neuropathy in paraneoplastic syndromes), perinuclear anti-neutrophilic cytoplasmic antibodies, and cytoplasmic anti-neutrophilic cytoplasmic antibodies. We have reported a 12% incidence of a predominantly motor form of neuropathy in patients with diabetes associated with monosialoganglioside antibodies (22). Furthermore, we previously found that sera with high titers of phospholipase antibody inhibited the growth and differentiation of neuroblastoma cells in culture (23). Unfortunately, this is so commonplace that the issue has been raised that phospholipase antibodies do not directly contribute to nerve damage and that they are formed as a result of antigen release from tissue damage. Pittenger et al. (24) reported on neurotoxicity of sera from 39 patients with diabetic neuropathy. Neurotoxicity was assessed using the NIE neuronal cell line (adrenal medulla and ventral spinal cord 4.1, a motor cell line). Neurotoxicity correlated with vibration detection thresholds and sera from patients with motor neuropathy were highly toxic to the VSC 4.1 line, indicating that there was a relationship between the specific nerve fiber function and the type of neuronal cell killed by the serum factors. Unfortunately, there have been no trials on immunotherapy for somatic neuropathies to confirm or refute the importance of these findings.


   AUTONOMIC NEUROPATHY
TOP
 INTRODUCTION
 PROXIMAL NEUROPATHIES
 SOMATIC NEUROPATHIES
 AUTONOMIC NEUROPATHY
REFERENCES
 
The relationship between autoimmunity and development of autonomic neuropathy has historically been stronger than somatic neuropathies and was first suggested in the early 1980s with the report of coincident autoimmune iridocyclitis and diabetic autonomic neuropathy (25). Autoantibodies against autonomic structures are frequently found in diabetes, although rare in type 2 diabetes (26). However, whether these antibodies lead to autonomic dysfunction is not clearly known. Retesting of neural and adrenal antibodies in diabetic autonomic neuropathy demonstrated that once present, these antibodies normally persist in these individuals; most patients who were negative at the beginning remained negative. We have previously identified the frequent occurrence of phospholipid antibodies in diabetic patients and demonstrated the positive correlation of these antibodies to the extent of neuropathy (23). Furthermore, we also reported that autoimmune neuronal destruction may contribute to the development of autonomic neuropathy in type 1 diabetes (17). Anti-sympathetic and -parasympathetic antibodies are relatively specific for type 1 diabetes, and there is evidence to suggest that these antibodies can be associated with dysautonomia. At the same time, there are many reports that dispute this and claim that antibodies against autonomic nervous system antigens are an inconsistent feature of diabetes (27). Hypoglycemia unawareness in the presence of anti–adrenal medullary antibodies (28) and diminished catecholamine output with orthostasis (29) in individuals with anti–sympathetic nervous system antibodies provide some evidence in support of the pathogenic role of autoantibodies. Furthermore, it is believed that autoimmune nerve destruction may be involved in diabetic neuropathy, even in type 2 diabetic patients, as parasympathetic nerve antibodies were found to be related to the severity of parasympathetic neuropathy in these patients (30,31). Surprisingly, the frequency of sympathetic nerve antibodies was low in type 1 diabetic patients (31). The finding of similar frequencies of Ig binding to adrenal medulla in both type 1 and type 2 diabetic patients, as well as in normal control subjects, argues against specificity of these autoantibodies (32). No association was demonstrated between anti–vagus nerve, anti–sympathetic ganglion, and anti-adrenal autoantibodies with retinopathy, peripheral somatic neuropathy, or nephropathy, even though they were frequently present in type 1 diabetes (33).

Neuronal acetylcholine receptor (AchR) antibodies are considered a novel serologic marker of neurologic autoimmunity, but the pathogenicity of neuronal AchR autoantibodies in autonomic neuropathy has not been established (34). It has been shown that patients with orthostatic hypotension and prominent cholinergic dysautonomia are most likely to be seropositive for ganglionic AchR antibodies (35) and that higher antibody titers correlated with greater autonomic dysfunction and more frequent cholinergic dysautonomia (36).

Immune responses driven by distinct neuronal AChR (ganglionic nicotinic AChR) subtypes expressed in small-cell carcinomas account for autoimmune autonomic neuropathy, as well as seizures, dementia, and movement disorders (37). Antibodies to this receptor can also interfere with ganglionic neurotransmission and produce autoimmune autonomic neuropathy (38).

Among other antibodies, autoantibodies against amphiphysin I and II have been associated with sensory motor neuropathy (39). The anti–Sc 170 and anti-U1snRNP antibodies are associated with esophageal motor dysfunction and cardiovascular autonomic neuropathy (40). Autoantibodies that activate smooth muscle L-type calcium channels produced specifically by type 1 diabetic patients may mediate gastrointestinal and autonomic dysfunction in these patients (41). Autoantibodies to nerve growth factor may play a role in diabetic autonomic neuropathy and may be a feature of evolving but not established neuropathy (42).

In this issue of Diabetes Care, Granberg et al. (43) provide epidemiological data to support the implication of autoimmunity in autonomic neuropathy. They examined 41 patients for a period of 14 years and assessed, among other measures, heart rate variability, vasoconstrictor response to cooling, and acceleration of the brake index, which was measured as the heart rate reaction to postural change at intervals over 14 years. Fifty-six percent of patients had antibodies to autonomic nervous system of some sort: sympathetic ganglion, vagus nerve, or adrenal medulla. What the authors show is that an index of autonomic neuropathy is 7.5 times more likely to become abnormal in patients who are autoantibody positive than those who are autoantibody negative. The authors did not, however, determine whether patients had autonomic nervous system antibodies at their first visit and whether this correlated to the progression of autonomic neuropathy, and they did not show the appearance and disappearance of these antibodies over time. In certain subtypes of type 1 diabetes, antibodies that are present in the beginning subsequently disappear. It is difficult to argue post hoc ergo propter hoc because antibodies may be secondary to damage to the autonomic nervous system that is occurring for other reasons. Nonetheless, this is a very interesting report suggesting that antibodies predict the evolution and development of autonomic nervous system dysfunction. The authors fall short of demonstrating that the course of autonomic neuropathy can be reversed or abrogated by therapies directed at autoimmune neuropathy and, for this reason, do not fulfill the criteria for cause and effect now evident with proximal neuropathies.

Autoimmunity in diabetic neuropathy has always been a bridesmaid but never a bride. The article by Granberg et al. (43) suggests a predictive association. The ultimate proof of the relevance of circulating antibodies to neuronal structures will rest with identification of the specific antigen and reversal of diabetic neuropathies with neutralization of the antibody to the antigen.

Received for publication March 29, 2005. Accepted for publication April 30, 2005.


   REFERENCES
TOP
 INTRODUCTION
 PROXIMAL NEUROPATHIES
 SOMATIC NEUROPATHIES
 AUTONOMIC NEUROPATHY
 REFERENCES
 

  1. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7:497–508, 2005[Medline]
  2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, the American Diabetes Association: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962, 2005[Free Full Text]
  3. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O’Brien PC, Melton LJ 3rd, Service FJ: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43:817–824, 1993[Abstract/Free Full Text]
  4. Watkins PJ: Progression of diabetic autonomic neuropathy. Diabet Med 10 (Suppl. 2):77S–78S, 1993
  5. Levitt NS, Stansberry KB, Wychanck S, Vinik AI: Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM. Diabetes Care 19:751–754, 1996[Abstract]
  6. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257–267, 1996[Abstract]
  7. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycosylation: glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 256:205–212, 1988[Medline]
  8. Vinik A, Erbas T, Stansberry KB, Pittenger G: Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 109 (Suppl. 2):S451–S473, 2001
  9. Vinik A, Pittenger G, Stansberry K, Park TS, Erbas T: Neurotrophic factors. In Textbook of Diabetic Neuropathy. Stuttgart, Germany, Georg Thiem Verlag, 2003, p. 129–169
  10. Waksman BH, Adams RD: Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 102:213–236, 1955[Abstract]
  11. Donev SR: Ultrastructural evidence for the presence of a glial sheath investing the islets of Langerhans in the pancreas of mammals. Cell Tissue Res 237:343–348, 1984[Medline]
  12. Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, Sampson A, Afifiyan F, Elford A, Jackowski G, Becker DJ, Santamaria P, Ohashi P, Dosch HM: Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 9:198–205, 2003[Medline]
  13. Hoeldtke RD, Bryner KD, Horvath GG, Byerly MR, Hobbs GR, Marcovina SM, Lernmark A: Antibodies to GAD and glycemic control in recent-onset IDDM. Diabetes Care 20:1900–1903, 1997[Abstract]
  14. Hoeldtke RD, Bryner KD, Hobbs GR, Horvath GG, Riggs JE, Christie I, Ganser G, Marcovina SM, Lernmark A: Antibodies to glutamic acid decarboxylase and peripheral nerve function in type 1 diabetes. J Clin Endocrinol Metab 85:3297–3308, 2000[Abstract/Free Full Text]
  15. Jaeger C, Allendorfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzel RG: Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 29:510–515, 1997[Medline]
  16. Zanone MM, Burchio S, Quadri R, Pietropaolo M, Sacchetti C, Rabbone I, Chiandussi L, Cerutti F, Peakman M: Autonomic function and autoantibodies to autonomic nervous structures, glutamic acid decarboxylase and islet tyrosine phosphatase in adolescent patients with IDDM. J Neuroimmunol 87:1–10, 1998[Medline]
  17. Pittenger GL, Liu D, Vinik AI: The neuronal toxic factor in serum of type 1 diabetic patients is a complement-fixing autoantibody. Diabet Med 12:380–386, 1995[Medline]
  18. Pittenger GL, Liu D, Vinik AI: The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas-mediated. J Neuroimmunol 76:153–160, 1997[Medline]
  19. Sharma K, Cross J, Farronay O, Ayyar D, Sheber R, Bradley W: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 59:758–765, 2002[Abstract/Free Full Text]
  20. Chin RL, Latov N: Peripheral neuropathy and celiac disease. Curr Treat Options Neurol 7:43–48, 2005[Medline]
  21. Sharma K, Cross J, Ayyar D, Martinez-Arizala A, Bradley W: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 59:751–757, 2002[Abstract/Free Full Text]
  22. Milicevic Z, Newlon PG, Pittenger GL, Stansberry KB, Vinik AI: Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features. Diabetologia 40:1364–1365, 1997[Medline]
  23. Vinik AI, Pittenger GL, Stansberry KB, Powers A: Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Diabetes Care 18:1225–1232, 1995[Abstract]
  24. Pittenger GL, Burcus N, Malik R, Vinik AI: Cytotoxicity of serum on sensory/autonomic and motor neural cells in vitro predicts sensory neuropathy. (Abstract). Diabetes 46 (Suppl. 1):125A, 1997
  25. Guy RJC, Richards F, Edmonds ME, Watkins PJ: Diabetic autonomic neuropathy and iritis: an association suggesting an immunological cause. Br Med J (Clin Res Ed) 289:343–345, 1984
  26. Cachia MJ, Peakman M, Zanone M, Watkins PJ, Vergani D: Reproducibility and persistence of neural and adrenal autoantibodies in diabetic autonomic neuropathy. Diabet Med 14:461–465, 1997[Medline]
  27. Stroud CR, Heller SR, Ward JD, Hardisty CA, Weetman AP: Analysis of antibodies against components of the autonomic nervous system in diabetes mellitus. QJM 90:577–585, 1997[Abstract/Free Full Text]
  28. De Riva C: Hypoglycaemia unawareness in a young boy with insulin-dependent diabetes mellitus and anti-adrenal medullary antibodies. Diabetes Metab 23:528–532, 1997[Medline]
  29. Brown FM, Brink SJ, Freeman R, Rabinowe SL: Anti-sympathetic nervous system autoantibodies: diminished catecholamines with orthostasis. Diabetes 38:938–941, 1989[Abstract]
  30. Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M, Fujii M, Yoshimori K, Hasegawa G, Nakamura N, Kitagawa Y, Kondo M: Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 20:1896–1899, 1997[Abstract]
  31. Sundkvist G, Lind P, Bergstrom B, Lilja B, Rabinowe SL: Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients. J Intern Med 229:505–510, 1991[Medline]
  32. Husebye ES, Winqvist O, Sundkvist G, Kampe O, Karlsson FA: Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: no evidence for an association with autonomic neuropathy. J Intern Med 239:139–146, 1996[Medline]
  33. Ejskjaer N, Arif S, Dodds W, Zanone MM, Vergani D, Watkins PJ, Peakman M: Prevalence of autoantibodies to autonomic nervous tissue structures in type 1 diabetes mellitus. Diabet Med 16:544–549, 1999[Medline]
  34. Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA: Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50:1806–1813, 1998[Abstract]
  35. Sandroni P, Vernino S, Klein CM, Lennon VA, Benrud-Larson L, Sletten D, Low PA: Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 61:44–48, 2004[Abstract/Free Full Text]
  36. Klein CM, Vernino S, Lennon VA, Sandroni P, Fealey RD, Benrud-Larson L, Sletten D, Low PA: The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53:752–758, 2003[Medline]
  37. Lennon VA, Ermilov LG, Szurszewski JH, Vernino S: Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 111:907–913, 2003[Medline]
  38. Goldstein DS, Holmes C, Dendi R, Li ST, Brentzel S, Vernino S: Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clin Auton Res 12:281–285, 2002[Medline]
  39. Perego L, Previtali SC, Nemni R, Longhi R, Carandente O, Saibene A, Sciolla R, Villa A, Gai P, Panzeri C, Dell’Antonio G, Quattrini A, Folli F: Autoantibodies to amphiphysin I and amphiphysin II in a patient with sensory-motor neuropathy. Eur Neurol 47:196–200, 2002[Medline]
  40. Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G: Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol 27:692–697, 2000[Medline]
  41. Jackson MW, Gordon TP, Waterman SA: Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes. Gastroenterology 126:819–828, 2004[Medline]
  42. Zanone MM, Banga JP, Peakmen M, Edmonds M, Watkins PJ: An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. Diabet Med 11:378–383, 1994[Medline]
  43. Granberg V, Ejskjaer N, Peakman M, Sundkvist G: Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 28:XXXX–XXXX, 2005
  44. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA: Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343:847–855, 2000[Abstract/Free Full Text]
  45. Vernino S, Cheshire WP, Lennon VA: Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 88:187–192, 2001[Medline]
  46. Bogousslavsky J, Regli F, Doret AM, Fulpius BW, Ostinelli B, Rabinowicz T, Ruzicka J: Encephalopathy, peripheral neuropathy, dysautonomia, myasthenia gravis, malignant thymoma, and antiacetylcholine receptor antibodies in the CSF. Eur Neurol 22:301–306, 1983[Medline]
  47. O’Suilleabhain P, Low PA, Lennon VA: Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 50:88–93, 1998[Abstract/Free Full Text]
  48. Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH: Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467–1474, 1995[Abstract/Free Full Text]
  49. Kaiser R: [Paraneoplastic neurologic syndromes: diagnostic and pathogenetic significance of autoantibodies] (Review). Nervenarzt 70:688–701, 1999 [article in German][Medline]
  50. Antoine JC, Camdessanche JP: [Paraneoplastic peripheral neuropathies] (Review). Rev Neurol (Paris )160:188–198, 2004 [article in French][Medline]
  51. Camdessanche JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, Michel D: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 125:166–175, 2002[Abstract/Free Full Text]
  52. Winkler AS, Dean A, Hu M, Gregson N, Chaudhuri KR: Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases. Clin AutonRes 11:115–118, 2001
  53. Lucchinetti CF, Kimmel DW, Lennon VA: Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50:652–657, 1998[Abstract/Free Full Text]
  54. Kusunoki S, Kanazawa I: [Carcinomatous autonomic neuropathy and the autoantibodies in paraneoplastic neuropathy] (Review). Nippon Rinsho 50:834–839, 1992 [article in Japanese][Medline]
  55. Dalmau J, Clouston PD: Paraneoplastic syndromes (Letter). Neurology 42:1429, 1992
  56. Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB: Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology 38:1391–1398, 1988[Abstract/Free Full Text]
  57. Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 47:297–305, 2000[Medline]
  58. Uncini A, Santoro M, Corbo M, Lugaresi A, Latov N: Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 16:610–615, 1993[Medline]
  59. Vernino S, Lennon VA: Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 10:7270–7275, 2004[Abstract/Free Full Text]
  60. Zanone MM, Peakman M, Purewal T, Watkins PJ, Vergani D: Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:564–569, 1993[Medline]
  61. Antoine JC, Camdessanche JP, Ferraud K, Caudie C: Antiganglioside antibodies in paraneoplastic peripheral neuropathies. J Neurol Neurosurg Psychiatry 75:1765–1767, 2004[Abstract/Free Full Text]
  62. Kusunoki S, Chiba A, Tai T, Kanawawa I: Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve 16:752–756, 1993[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vinik, A. I.
Right arrow Articles by Ullal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vinik, A. I.
Right arrow Articles by Ullal, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum